Business

Avanir Pharmaceuticals has paid $20 million up front to OptiNose for an exclusive North American license for development and commercialization of OptiNose’s intranasal low-dose sumatriptan powder for the treatment of acute migraines. OptiNose could receive… Read more . . .

Jabil Circuit has announced the completion of its $665 million acquisition of contract plastics manufacturer Nypro, which makes dry powder inhalers and nasal spray pumps for pharmaceutical companies among other products. According to Jabil, it… Read more . . .

Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015.… Read more . . .

The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for… Read more . . .

Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin… Read more . . .

Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson’s disease patients, the company… Read more . . .

Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and… Read more . . .

Shareholders of Elan Corporation have rejected the company’s $1 billion deal for royalties from Theravance inhaled drugs, including the Breo and Anoro Ellipta DPIs. Anticipating the result from the Theravance vote, Elan announced on June… Read more . . .

So many shareholders have already voted against Elan’s proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan… Read more . . .

AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if… Read more . . .